Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and safety of intranasal diazepam (NRL-1) in healthy Japanese subjects
jRCT2031220272Phase 1Completed
- Sponsor
- Aculys Pharma, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of diazepam in status epilepticus (SE) and seizure disorder, sponsored by Aculys Pharma, Inc. Primary endpoint: Primary pharmacokinetic parameters and dose proportionality. Started Sep 2022; status: completed.
02
Drugs
diazepam
03
Conditions
status epilepticus (SE)seizure disorder
Beyond the preview
Go deeper on jRCT2031220272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220272.